INSMED INC (INSM)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for INSM
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| INSM | Director | 62 | ["more than 30 years of experience in investment banking, corporate finance and business development", "significant experience in financing and equity capital markets in the pharmaceutical and biotechnology industries", "recent cybersecurity training"] | ["Audit", "Compensation", "Audit Committee", "Nominations and Governance Committee"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| IMNM | Director | 61 | ["Vice Chair, Equity Capital Markets at Wells Fargo Securities (2007-2018)","Vice President of Finance and Business Development at Lexicon Pharmaceuticals (2003-2007)","Managing Director of Equity Capital Markets at J.P. Morgan","Board member of Kura Oncology since June 2021","Board member of Insmed Incorporated since April 2020","Board member of Repare Therapeutics Inc. since March 2019","Previous board member of Idera Pharmaceuticals (Dec 2018 - Sep 2022)","Previous board member of Five Prime Therapeutics until its acquisition in April 2021","M.B.A from New York University’s Stern School of Business","B.A. in mathematics and computer science from Boston College"] | ["Audit (Chair)","Nominating and Corporate Governance"] | 2025 |
Biography sourced from the proxy statement filing.
Age: 62 Director Since: April 2020 Committees: Member of the Audit Committee Member of the Nominations and Governance Committee Current Public Board Service: Director, Kura Oncology, Inc. (Nasdaq: KURA) Director, Immunome, Inc. (Nasdaq: IMNM) Recent Public Board Service: Director until September 2022, Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) Director until April 2021, Five Prime Therapeutics, Inc. (Nasdaq: FPRX) (acquired by Amgen, Inc. (Nasdaq: AMGN)) Director until January 2026, Repare Therapeutics, Inc. (Nasdaq: RPTX) (acquired by XenoTherapeutics, Inc.) Qualifications: Ms. Schafer has more than 30 years of experience in investment banking, corporate finance and business development, including significant experience in financing and equity capital markets in the pharmaceutical and biotechnology industries; these qualifications, in addition to her recent cybersecurity training, make her a valuable asset to the Board. Education: Boston College - B.A., mathematics and computer science New York University Stern School of Business - M.B.A. NYU Law - Nasdaq Cyber Scholar Program Career Highlights: Hyphen Advisors, LLC (2018 - present) Managing Partner Wells Fargo Securities (2007 - 2018) Vice Chair, Equity Capital Markets Managing Director Lexicon Pharmaceuticals (Nasdaq: LXRX) (2003 - 2007) Vice President, Finance and Business Development J.P. Morgan (1986 - 2003) Managing Director, Equity Capital Markets Sector Head Vice President